Clomacran

CHEMBL1615350 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
300.8 g/mol
LogP
4.6
Phase
4

An antipsychotic agent belonging to the phenothiazine class used to treat psychiatric conditions. It helps manage symptoms such as hallucinations and disordered thinking.

น้ำหนักโมเลกุล

300.8000 g/mol

LogP

4.60

TPSA

15.30 Ų

Lipinski RO5

ผ่าน

กลไกการออกฤทธิ์

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCCC1c2ccccc2Nc2ccc(Cl)cc21

InChI

InChI=1S/C18H21ClN2/c1-21(2)11-5-7-14-15-6-3-4-8-17(15)20-18-10-9-13(19)12-16(14)18/h3-4,6,8-10,12,14,20H,5,7,11H2,1-2H3

Molecular Formula

C18H21ClN2

HBD / HBA

1 / 2

พันธะที่หมุนได้

4

อะตอมหนัก

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

An antipsychotic agent belonging to the phenothiazine class used to treat psychiatric conditions. It helps manage symptoms such as hallucinations and disordered thinking.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Clomacran is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1615350. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 21382. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.